

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

November 14, 2016

Department of Corporate Services
Corporate Relation Department
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

The Executive Director,
Ahmedabad Stock Exchange Ltd.
First Floor, Kamdhenu Complex
Opp. Sahjanand College
Panjara Pole
Ahmedabad – 380 015

Dear Sir,

Sub. : Unaudited Financial Results of the Company for the Quarter and Half Year ended on 30th September, 2016 along with Limited Review Report pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Please find enclosed herewith Unaudited Financial Results of the company for Quarter and Half Year ended on 30th September, 2016 along with Limited Review Report was approved and adopted pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The said results were considered and approved by the Board of Directors of the Company at its meeting held on 14th November, 2016 and have been reviewed by the Auditors of the Company. The said Financial Results will be released for publishing in the Newspapers and same will be uploaded on the website of the Company.

You are requested to take the same on record.

Thanking You,

Yours Faithfully
For **BACIL PHARMA LIMITED**



Director



Enclosure: As above

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

Unaudited Financial Results for the quarter ended 30th September 2016

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Yearly Ended		Year ended 31/03/16 Audited
		30/09/16 Unaudited	30/06/16 Unaudited	30/09/15 Unaudited	30/09/16 Unaudited	30/09/15 Unaudited	
1.	Income						
	a) Net Sales/Income from Operations	---	---	---	---	---	---
	b) Other Operating Income	---	---	---	---	---	---
	Total Income	---	---	---	---	---	---
2.	Expenditure						
	a) Increase/decrease in stock and work in progress	---	---	---	---	---	---
	b) Consumption of raw materials	---	---	---	---	---	---
	c) Purchase of traded goods	---	---	---	---	---	---
	d) Employees cost	---	---	---	---	---	---
	e) Depreciation	0.08	0.07	0.02	0.15	0.04	0.08
	f) Other expenditure	1.93	5.50	2.99	7.43	6.83	12.88
	Total Expenditure	2.01	5.57	3.01	7.58	6.87	12.96
3.	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	- 2.01	- 5.57	- 3.01	- 7.58	- 6.87	- 12.96
4.	Other Income	2.80	1.05	1.46	3.85	2.45	6.25
5.	Profit before Interest and Exceptional Items (3+4)	0.79	- 4.52	- 1.55	- 3.73	- 4.42	- 6.71
6.	Interest	---	---	---	---	---	---
7.	Profit after Interest but before Exceptional Items (5-6)	0.79	- 4.52	- 1.55	- 3.73	- 4.42	- 6.71
8.	Exceptional items	---	---	---	---	---	---
9.	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	0.79	- 4.52	- 1.55	- 3.73	- 4.42	- 6.71
10.	Tax expense	---	---	---	---	---	---
11.	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	0.79	- 4.52	- 1.55	- 3.73	- 4.42	- 6.71
12.	Extraordinary Item (net of tax expense Rs. _____)	---	---	---	---	---	---
13.	Net Profit(+)/ Loss(-) for the period (11-12)	0.79	- 4.52	- 1.55	- 3.73	- 4.42	- 6.71
14.	Paid-up equity share capital (F.V. Rs.10/- per share)	589.00	589.00	589.00	589.00	589.00	589.00
15.	Reserve excluding Revaluation Reserves	---	---	---	---	---	- 12.92
16.	Earning Per Share (before & after extraordinary items) (of ₹ each) – Not Annualised (in ₹) Basic and Diluted	- 0.03	- 0.05	- 0.03	- 0.10	- 0.08	- 0.11
17.	Public Shareholding						
	- No. of shares	32,57,500	32,57,500	32,46,300	32,57,500	32,46,300	32,57,001
	- Percentage of shareholding	55.31%	55.31%	55.12%	55.31%	55.12%	55.30%
18.	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered						
	- Number of shares	26,32,500	26,32,500	26,43,700	26,32,500	26,43,700	26,32,999
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	44.69%	44.69%	44.88%	44.69%	44.88%	44.70%

Note:

- The above results were reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on November 14, 2016.
- The Statutory Auditors of the Company have conducted a "Limited Review" of the aforesaid results for the half year ended September 30, 2016.
- No commercial activities were carried out at the plant of the company and hence depreciation on Plant & Machinery is not provided.
- There are no separate reportable segments.
- There are no investor complaints received or lying unresolved at the end of quarter.
- Statement of Assets and Liabilities as on September 30, 2016 is also attached herewith.

For BACIL PHARMA LIMITED

Place: Mumbai
Dated: November 14, 2016



[Signature]
Director

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI – 400 001.

Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427 Tel.: 22618452/22661541, Tel/Fax: 22618327

STATEMENT OF ASSETS AND LIABILITIES

(₹ in Lakhs)			
Sr. No.	Particulars	As At 30/09/2016	As At 31/03/2016
A	EQUITY AND LIABILITIES		
(1)	Shareholders Funds		
	(a) Share Capital	652.71	652.71
	(b) Reserves and Surplus	- 16.65	- 12.91
(2)	Non Current Liabilities		
	(a) Long Term Borrowings	---	---
	(b) Deferred Tax Liabilities (Net)	---	---
(3)	Current Liabilities		
	(a) Short Term Borrowings	33.90	27.15
	(b) Trade Payables	---	---
	(c) Other Current Liabilities	0.41	1.17
	(d) Short Term Provisions	0.36	1.21
	TOTAL EQUITY AND LIABILITIES	670.73	669.34
B	ASSETS		
(1)	Non Current Assets		
	(a) Fixed Assets	593.74	593.51
	(b) Non Current Investments	50.73	50.73
	(c) Deferred Tax Assets (Net)	---	---
	(d) Long Term Loans and Advances	---	---
	(e) Other non Current Assets	---	---
(2)	Current Assets		
	(a) Current Investment	---	---
	(b) Inventories	---	---
	(c) Trade Receivables	---	---
	(d) Cash and Cash Equivalent	2.54	2.43
	(e) Short Term Loans and Advances	22.75	21.70
	(f) Other Current Assets	0.97	0.97
	TOTAL ASSETS	670.73	669.34

For BACIL PHARMA LTD.




Director

LIMITED REVIEW REPORT

Ref.: BACIL PHARMA LIMITED

"We have reviewed the accompanying statement of un-audited financial results of BACIL PHARMA LIMITED for the quarter ended 30th September, 2016. This statement is the responsibility of the Company's management and has been approved by the Board of Directors.

A review of interim financial information consists principally of applying analytical procedures for financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement".

For A. W. KETKAR & CO.
CHARTERED ACCOUNTANTS



A. W. KETKAR
Proprietor

Place : Mumbai
Dated: November 14, 2016